Generic Drugs
Latest news, explainers and analysis on Generic Drugs. Tracking 4 stories on Arth Vani.
Connected in the graph
Latest on Generic Drugs
Glenmark US Subsidiary to Pay ₹127 Crore in Generic Drug Antitrust Settlement
Glenmark Pharmaceuticals' US subsidiary has agreed to pay $15.28 million, equivalent to approximately ₹127 crore, to settle an antitrust lawsuit filed by Humana. The litigation involved allegations related to generic drug pricing and market allocation in the United States.
BreakingTrump Tariff Threat Sinks Indian Pharma Stocks; Nifty Pharma Index Falls
Indian pharmaceutical shares declined on Wednesday following US President Trump's announcement of proposed tariffs, including a potential 100% levy, on generic drugs. This move has particularly spooked investors and highlighted the vulnerability of Indian drugmakers with significant revenue exposure to the US market. Analysts are now advising a focus on domestically oriented pharmaceutical firms.
BreakingTrump's Proposed 200% Tariff Threatens $9.7 Billion Indian Pharma Exports by 2028
Former US President Donald Trump's proposed 200% tariff on imported generic drugs could put India's significant $9.7 billion generic drug exports to the United States at risk starting 2028. Indian pharmaceutical companies have a two-year window to explore new markets and adapt, while US patients and insurers may face increased healthcare costs.
Alembic & NATCO Get USFDA Nod for Cancer Drug; Big Market Opportunity
Indian pharmaceutical firms Alembic Pharmaceuticals and NATCO Pharma have received tentative USFDA approval for a generic version of the cancer drug Olaparib. This approval opens up a significant market opportunity in the US, estimated at ₹11,660 crore, though the commercial launch is contingent on ongoing legal proceedings.
Loan interest rates, processing fees and eligibility are set by the lender and subject to credit approval — verify current terms before applying. Some listings may be sponsored. Not financial advice.